Drugs / BAY987521
last change Jan 2017 re-read 3 minutes ago

BAY987521

Investigated by
Bayer

Trials 13

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase not applicable13 trials
— NCT02995044 Jan 2017 — Bayer Terminated No outcome recorded
— NCT02995109 Jan 2017 — Bayer Completed No outcome recorded
— NCT02995018 Jan 2017 — Bayer Completed No outcome recorded
— NCT02995031 Jan 2017 — Bayer Terminated No outcome recorded
— NCT02995148 Dec 2016 → Jan 2017 — Bayer Completed No outcome recorded
— NCT02995161 Dec 2016 → Jan 2017 — Bayer Completed No outcome recorded
— NCT02936557 Oct → Nov 2016 — Bayer Completed No outcome recorded
— NCT02936583 Oct → Nov 2016 — Bayer Completed No outcome recorded
— NCT02936570 Oct → Nov 2016 — Bayer Completed No outcome recorded
— NCT02936544 Oct → Nov 2016 — Bayer Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 13 sources stand behind the page.

FieldValueCited text
Known as BAY987521 ClinicalTrials.gov intervention name — accepted as the source's own label NCT02936544 ↗
12

NCT02936570 ↗

NCT02995148 ↗

NCT02995109 ↗

NCT02995031 ↗

NCT02774252 ↗

NCT02995018 ↗

NCT02760576 ↗

NCT02936557 ↗

NCT02854137 ↗

NCT02995044 ↗

Show 2 more sources

Route Topical “The application of test material is 2 mg/cm\*2.” NCT02774252 ↗